To be clear, the University of Pittsburgh researcher who reported the strange illness in his lab rats is in NO way connected to coronavirus research in this country or abroad. He and his rats were victims of a disease that appears to have been spreading along research channels that involved his institution. He and his co-authors were abused and threatened so badly that they withdrew the paper even though it had been peer-reviewed.
Background on Zhou's work:
Chinese Military Scientist Filed Patent For A Vaccine Soon After China Revealed Covid-19 Details in 2020
Bhaswati Guha Majumder
5 June 2021
According to documents obtained by The Weekend Australian, Zhou Yusen, a respected military scientist for the People’s Liberation Army (PLA) who collaborated with the controversial Wuhan Institute of Virology (WIV) and American experts, submitted a patent for a Covid-19 vaccine on 24 February last year.
The scientist later died under mysterious circumstances in May 2020.
Despite Zhou’s status as an award-winning military scientist, there were no reports or tributes, with him only being labelled as “dead” in a Chinese media item from July and a scientific publication from December last year.
However, the report revealed that the patent, filed by the PLA’s Institute of Military Medicine, was lodged just five weeks after China acknowledged human-to-human transmission of the novel virus.
Professor Nikolai Petrovsky from Flinders University told the paper: “This is something we have never seen achieved before, raising the question of whether this work may have started much earlier”.
Additionally, the report said that Zhou worked as a postdoctoral researcher at the University of Pittsburgh School of Medicine and collaborated with the New York Blood Center before joining the PLA.
Zhou also collaborated closely with the Wuhan lab, which has come under increased international scrutiny for its role in the pandemic, as well as the famous “batwoman” or the Chinese virologist Shi Zhengli…https://in.news.yahoo.com/chinese-mi...082549951.html
Bility paper describing mysterious disease in his immune suppressed/human chimera rats:
Figure 1: The spatiotemporal dynamics of COVID-19-like disease in laboratory rats in the absence of experimental induction. We recorded COVID-19-like symptoms (namely, labored/difficulty breathing and hemorrhaging-blood around nose) in laboratory rats via syndromic surveillance that included three times per day visual monitoring. (A) The values denote the total numbers of rats that developed COVID-19-like symptoms in a given month. (B) the values denote the total number of rats that developed COVID-19-like disease and the total number of rats that did not developed disease (healthy) for a given room location. The fisher’s exact test P value = <0.0001. The result is significant at p < .05.Upon recording the COVID-19-like disease, the rats were immediately sacrificed (per humane research guildelines) and the COVID-19-like pathologies in the thoracic organs were confirmed via necropsy. The rat colony was not designed beforehand to study COVID-19-like disease, and the syndromic surveillance procedures were instituted as a general welfare check to insure a healthy colony. The rats were housed at approximately equal ratio in two adjacent rooms. The total number of rats observed in the study period was ~ 92 and ~46 per sex. The COVID-19-like disease was recorded predominately in one room. Animals were handled by the same staff (in biosafety level 2 personal protective equipment). The rats were house in autoclaved microisolator cages on steel (iron alloy) racks, and always handled in a biosafety cabinet-Class 2, provided autoclaved bedding and water, and sterilized food.
Figure 2: The sex differences in COVID-19-like disease in a laboratory rats in the absence of experimental induction.We recorded the COVID-19-like symptoms (namely, labored difficulty breathing and hemorrhaging-blood around nose) predominately in male (M) rats (13 of 46 males), compared to female (F) rats (4 of 46 females) despite approximately equal number of both sexes in the colony. The fisher’s exact test P value = 0.03. The result is significant at p < .05.
The COVID-19-like disease disproportionally affected males, which recapitulates the COVID-19-induced morbidity and mortality in humans (Figure 2). The COVID-19-like disease in the rats occurred rapidly, with rats exhibiting excellent health status (normal movement, breathing, eating, and drinking) in the prior evening, but incapable of breathing and hemorrhaging (and seizure in one case) by the next morning. Gross, histological, and immunohistochemistry analysis of the major organs in the COVID-19-like diseased rats demonstrate significant blood clotting, hardened tan gray/pale patches, and black-hemorrhagic patches in the lungs and kidneys, along with silicate/glass-like structures, and the presence of SARS-CoV-2-like antigens in the lung and kidney epithelium (Figure 3, 4, 5, 6), which recapitulates COVID-19 pathology and the associated SARS-CoV-2 infection in humans [55, 139, 143-148]. The silicate/glass-like structures in the lungs and kidneys of the COVID-19-like diseased rats mimic the various stages associated with serpentinization-mediated rock mineralization (Figure 7) [112]. Tissue iron analysis in the lung of a COVID-19-like diseased rat demonstrates the presence of ferric iron (Fe 3+) and iron oxides (golden brown/rust-like) particles coupled with the silicate/glass-like structures and patches with hemorrhagic infiltrates (Figure 7). The silicate/glass-like structures and iron oxides deposits in the lungs and kidneys of the COVID-19-like diseased rat are consistent with tissue pathologies in COVID-19-induced mortality [50, 51].
Figure 3: Gross pathology of a COVID-19-like disease in a laboratory rats in the absence of experimental induction. Representative gross analysis of lung (green arrow), heart (yellow arrow) and kidney (blue arrow) in a COVID-19-like diseased (n=17) rats demonstrates the presence thoracic organs damage (A), with lung and heart (B), and kidney (C) pathologies, including blood clots (red) highlighted. (D) Representative gross analysis of lung (green arrow), heart (yellow arrow) and kidney (blue arrow) in a healthy rat demonstrates the absence of lung, heart, and kidney pathology. (E) Representative gross analysis of lung (green arrow), heart (yellow arrow) and kidney (blue arrow) in a COVID-19-like diseased rat demonstrates the severe lung with hemorrhagic pathology, albeit the kidney and heart in this animal appear normal. Gross lung damage was recorded in 100% of the necropsy, while both gross lung and kidney damage was recorded in ~ 50% of the cases. Gross damage to the heart was recorded in a single animal. (F) Analysis of the blood (diluted at 1:1 using 20mM EDTA-anticoagulant) from a healthy rat demonstrates a lack of viscosity, with the blood flowing to the bottom of the tube after ~10 seconds following withdrawal. (G) On the contrary, analysis of the blood (also diluted at 1:1 using 20mM EDTA-anticoagulant) from a COVID-19-like diseased rat, demonstrates severe viscosity (viscous clot), with the blood unable to flow to the bottom of the tube after ~10 seconds, following withdrawal (G-Left panel) and ~10 minutes following storage at 4 degree Celsius in an inverted position (G-Middle panel); dilution of the blood at 1:10 using 20mM EDTA-anticoagulant further demonstrates that the blood immediately clots in less than 10 seconds, with the viscous clot lodged on the side of the tube (G-Right panel). Blood coagulation was recorded in ~50% of the COVID-19-like cases.
Figure 4: SARS-CoV-2-like Nucleocapsid antigen in COVID-19-like diseased laboratory rats in the absence of experimental induction. (A)Immunohistochemistry analysis of SARS-CoV-1/2 nucleocapsid (brown) in healthy (column 1) and COVID-19-like diseased rats (n=3, from November 2019, column 3) demonstrate the presence of the SARS-CoV-1/2 Nucleocapsid antigen in the lung epithelial cells and renaltubular epithelial cells in COVID-19-like diseased rats (black arrow). (B) Immunohistochemistry staining of the lung from COVID-19-like diseased rat (from November 2019, column 1-2) with the detection system (secondary antibody and the chromogen detector) in the absence (column 1, Minus Anti-NP) or presence (column 2, Plus Anti-NP) of anti-SARS-CoV-1/2 nucleocapsid primary antibody (brown) demostrates the specificity of the staining procedure. The staining of the lung from a healthy rat (column 3) with anti-SARS-CoV-1/2 nucleocapsid primary antibody and the detection system (secondary antibody and the chromogen detector) confirms the specificity of the staining procedure. (C)Immunohistochemistry analysis of SARS-CoV-1/2 nucleocapsid (brown) in COVID-19-like diseased rats (n=5, from March-July 2020) demonstrate the presence of the SARS-CoV-1/2 Nucleocapsid antigen in the lung epithelial cells and renaltubular epithelial cells in COVID-19-like diseased rats (black arrow). Note: Molecular diagnostics for SARS-CoV-2 antigen was not perform on all animals with the COVID-19-like disease. The specificity of the anti-SARS-CoV-1/2 nucleocapsid primary antibody was validated by Alejandro Best Rocha et al, 2020 in human samples.
https://www.researchgate.net/publica...ing_the_COVID-
Bility, Moses. (2020). Can Traditional Chinese Medicine provide insights into controlling the COVID-19 pandemic: Serpentinization-induced lithospheric long-wavelength magnetic anomalies in Proterozoic bedrocks in a weakened geomagnetic field mediate the aberrant transformation of biogenic molecules in COVID-19 via magnetic catalysis. 10.13140/RG.2.2.30887.09128.
Background on Zhou's work:
Chinese Military Scientist Filed Patent For A Vaccine Soon After China Revealed Covid-19 Details in 2020
Bhaswati Guha Majumder
5 June 2021
According to documents obtained by The Weekend Australian, Zhou Yusen, a respected military scientist for the People’s Liberation Army (PLA) who collaborated with the controversial Wuhan Institute of Virology (WIV) and American experts, submitted a patent for a Covid-19 vaccine on 24 February last year.
The scientist later died under mysterious circumstances in May 2020.
Despite Zhou’s status as an award-winning military scientist, there were no reports or tributes, with him only being labelled as “dead” in a Chinese media item from July and a scientific publication from December last year.
However, the report revealed that the patent, filed by the PLA’s Institute of Military Medicine, was lodged just five weeks after China acknowledged human-to-human transmission of the novel virus.
Professor Nikolai Petrovsky from Flinders University told the paper: “This is something we have never seen achieved before, raising the question of whether this work may have started much earlier”.
Additionally, the report said that Zhou worked as a postdoctoral researcher at the University of Pittsburgh School of Medicine and collaborated with the New York Blood Center before joining the PLA.
Zhou also collaborated closely with the Wuhan lab, which has come under increased international scrutiny for its role in the pandemic, as well as the famous “batwoman” or the Chinese virologist Shi Zhengli…https://in.news.yahoo.com/chinese-mi...082549951.html
Bility paper describing mysterious disease in his immune suppressed/human chimera rats:
Figure 1: The spatiotemporal dynamics of COVID-19-like disease in laboratory rats in the absence of experimental induction. We recorded COVID-19-like symptoms (namely, labored/difficulty breathing and hemorrhaging-blood around nose) in laboratory rats via syndromic surveillance that included three times per day visual monitoring. (A) The values denote the total numbers of rats that developed COVID-19-like symptoms in a given month. (B) the values denote the total number of rats that developed COVID-19-like disease and the total number of rats that did not developed disease (healthy) for a given room location. The fisher’s exact test P value = <0.0001. The result is significant at p < .05.Upon recording the COVID-19-like disease, the rats were immediately sacrificed (per humane research guildelines) and the COVID-19-like pathologies in the thoracic organs were confirmed via necropsy. The rat colony was not designed beforehand to study COVID-19-like disease, and the syndromic surveillance procedures were instituted as a general welfare check to insure a healthy colony. The rats were housed at approximately equal ratio in two adjacent rooms. The total number of rats observed in the study period was ~ 92 and ~46 per sex. The COVID-19-like disease was recorded predominately in one room. Animals were handled by the same staff (in biosafety level 2 personal protective equipment). The rats were house in autoclaved microisolator cages on steel (iron alloy) racks, and always handled in a biosafety cabinet-Class 2, provided autoclaved bedding and water, and sterilized food.
Figure 2: The sex differences in COVID-19-like disease in a laboratory rats in the absence of experimental induction.We recorded the COVID-19-like symptoms (namely, labored difficulty breathing and hemorrhaging-blood around nose) predominately in male (M) rats (13 of 46 males), compared to female (F) rats (4 of 46 females) despite approximately equal number of both sexes in the colony. The fisher’s exact test P value = 0.03. The result is significant at p < .05.
The COVID-19-like disease disproportionally affected males, which recapitulates the COVID-19-induced morbidity and mortality in humans (Figure 2). The COVID-19-like disease in the rats occurred rapidly, with rats exhibiting excellent health status (normal movement, breathing, eating, and drinking) in the prior evening, but incapable of breathing and hemorrhaging (and seizure in one case) by the next morning. Gross, histological, and immunohistochemistry analysis of the major organs in the COVID-19-like diseased rats demonstrate significant blood clotting, hardened tan gray/pale patches, and black-hemorrhagic patches in the lungs and kidneys, along with silicate/glass-like structures, and the presence of SARS-CoV-2-like antigens in the lung and kidney epithelium (Figure 3, 4, 5, 6), which recapitulates COVID-19 pathology and the associated SARS-CoV-2 infection in humans [55, 139, 143-148]. The silicate/glass-like structures in the lungs and kidneys of the COVID-19-like diseased rats mimic the various stages associated with serpentinization-mediated rock mineralization (Figure 7) [112]. Tissue iron analysis in the lung of a COVID-19-like diseased rat demonstrates the presence of ferric iron (Fe 3+) and iron oxides (golden brown/rust-like) particles coupled with the silicate/glass-like structures and patches with hemorrhagic infiltrates (Figure 7). The silicate/glass-like structures and iron oxides deposits in the lungs and kidneys of the COVID-19-like diseased rat are consistent with tissue pathologies in COVID-19-induced mortality [50, 51].
Figure 3: Gross pathology of a COVID-19-like disease in a laboratory rats in the absence of experimental induction. Representative gross analysis of lung (green arrow), heart (yellow arrow) and kidney (blue arrow) in a COVID-19-like diseased (n=17) rats demonstrates the presence thoracic organs damage (A), with lung and heart (B), and kidney (C) pathologies, including blood clots (red) highlighted. (D) Representative gross analysis of lung (green arrow), heart (yellow arrow) and kidney (blue arrow) in a healthy rat demonstrates the absence of lung, heart, and kidney pathology. (E) Representative gross analysis of lung (green arrow), heart (yellow arrow) and kidney (blue arrow) in a COVID-19-like diseased rat demonstrates the severe lung with hemorrhagic pathology, albeit the kidney and heart in this animal appear normal. Gross lung damage was recorded in 100% of the necropsy, while both gross lung and kidney damage was recorded in ~ 50% of the cases. Gross damage to the heart was recorded in a single animal. (F) Analysis of the blood (diluted at 1:1 using 20mM EDTA-anticoagulant) from a healthy rat demonstrates a lack of viscosity, with the blood flowing to the bottom of the tube after ~10 seconds following withdrawal. (G) On the contrary, analysis of the blood (also diluted at 1:1 using 20mM EDTA-anticoagulant) from a COVID-19-like diseased rat, demonstrates severe viscosity (viscous clot), with the blood unable to flow to the bottom of the tube after ~10 seconds, following withdrawal (G-Left panel) and ~10 minutes following storage at 4 degree Celsius in an inverted position (G-Middle panel); dilution of the blood at 1:10 using 20mM EDTA-anticoagulant further demonstrates that the blood immediately clots in less than 10 seconds, with the viscous clot lodged on the side of the tube (G-Right panel). Blood coagulation was recorded in ~50% of the COVID-19-like cases.
Figure 4: SARS-CoV-2-like Nucleocapsid antigen in COVID-19-like diseased laboratory rats in the absence of experimental induction. (A)Immunohistochemistry analysis of SARS-CoV-1/2 nucleocapsid (brown) in healthy (column 1) and COVID-19-like diseased rats (n=3, from November 2019, column 3) demonstrate the presence of the SARS-CoV-1/2 Nucleocapsid antigen in the lung epithelial cells and renaltubular epithelial cells in COVID-19-like diseased rats (black arrow). (B) Immunohistochemistry staining of the lung from COVID-19-like diseased rat (from November 2019, column 1-2) with the detection system (secondary antibody and the chromogen detector) in the absence (column 1, Minus Anti-NP) or presence (column 2, Plus Anti-NP) of anti-SARS-CoV-1/2 nucleocapsid primary antibody (brown) demostrates the specificity of the staining procedure. The staining of the lung from a healthy rat (column 3) with anti-SARS-CoV-1/2 nucleocapsid primary antibody and the detection system (secondary antibody and the chromogen detector) confirms the specificity of the staining procedure. (C)Immunohistochemistry analysis of SARS-CoV-1/2 nucleocapsid (brown) in COVID-19-like diseased rats (n=5, from March-July 2020) demonstrate the presence of the SARS-CoV-1/2 Nucleocapsid antigen in the lung epithelial cells and renaltubular epithelial cells in COVID-19-like diseased rats (black arrow). Note: Molecular diagnostics for SARS-CoV-2 antigen was not perform on all animals with the COVID-19-like disease. The specificity of the anti-SARS-CoV-1/2 nucleocapsid primary antibody was validated by Alejandro Best Rocha et al, 2020 in human samples.
https://www.researchgate.net/publica...ing_the_COVID-
Bility, Moses. (2020). Can Traditional Chinese Medicine provide insights into controlling the COVID-19 pandemic: Serpentinization-induced lithospheric long-wavelength magnetic anomalies in Proterozoic bedrocks in a weakened geomagnetic field mediate the aberrant transformation of biogenic molecules in COVID-19 via magnetic catalysis. 10.13140/RG.2.2.30887.09128.
Comment